Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
A Multicenter, Open-label, Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv Squamous Cell Carcinoma of H&N (SCCHN) Who Failed Pembro Monotherapy or Experiencing SD Following Completion of 4 to 8 Cycles of Pembro Monotherapy
Sponsor: HiberCell, Inc.
Terminated
Due to enrollment challenges resulting in changing treatment patterns, the study has been terminated. No patients remain on study.
Other terminated trials from HiberCell, Inc.
More terminations from HiberCell, Inc.
Other Squamous Cell Carcinoma of the Head and Neck trials with similar outcome
- NCT04659369 · Phase PHASE1 · Oct 2023
- NCT03862066 · Nov 2021
- NCT03179956 · Phase EARLY_PHASE1 · Jan 2019
- NCT02429089 · Phase PHASE1 · Sep 2018
- NCT01305772 · Phase PHASE2 · May 2012
Browse all Squamous Cell Carcinoma of the Head and Neck trials
A PHASE2 clinical study on Squamous Cell Carcinoma of the Head and Neck, this trial is terminated or withdrawn. The trial is conducted by HiberCell, Inc. and has accumulated 12 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jun 2022 [monthly]
Terminated PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2019 — Nov 2020 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Aug 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- HiberCell, Inc.
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .